2-(3-chlorophenyl)-histamine | 133118-40-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 2-(3-chlorophenyl)-histamine
• 英文别名: 2-<2-(3-chlorophenyl)-4-imidazolyl>ethanamine；2-(3-Chlorophenyl)histamine；2-[2-(3-chlorophenyl)-1H-imidazol-5-yl]ethanamine
• CAS: 133118-40-8
• 化学式: C₁₁H₁₂ClN₃
• 分子量: 221.689
• InChiKey: DHGUFKPZDMQBED-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  15
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.18
• 拓扑面积：
  54.7
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  1-acetoxy-4N-phthalimidobutan-2-one 、 (3-Chlorophenyl)(methoxy)methaniminium chloride 生成 2-(3-chlorophenyl)-histamine
  参考文献：
  名称：

  Histamine analogues. 33rd communication: 2-phenylhistamines with high histamine H1-agonistic activity

  摘要：

  DOI：

  10.1016/0223-5234(90)90132-m

文献信息

• IMPROVING THE TOLERABILITY OF MIRTAZAPINE AND A SECOND ACTIVE BY USING THEM IN COMBINATION
  申请人：Cypress Bioscience, Inc.

  公开号：EP2167096A1

  公开（公告）日：2010-03-31
• TOLERABILITY OF MIRTAZAPINE AND A SECOND ACTIVE BY USING THEM IN COMBINATION
  申请人：Rao Srinivas

  公开号：US20090275562A1

  公开（公告）日：2009-11-05

  A reduction in the side effects of treating with an agent having combined 5HT 2 /5HT 3 and alpha-2 antagonistic activity is obtained by administering an agent having selective norepinephrine reuptake inhibitory or histamine H1 agonist activity. In some embodiments, the invention provides synergistic combinations of 5HT 2 /5HT 3 antagonist/alpha-2 antagonist and selective norepinephrine reuptake inhibitor or histamine H1 agonist.
• TOLERABILITY OF MIRTAZAPINE AND A SECOND ACTIVE AGENT BY USING THEM IN COMBINATION
  申请人：Barak Nir

  公开号：US20100204205A1

  公开（公告）日：2010-08-12

  A reduction in the side effects of treating with an agent having combined 5HT2/5HT3 and alpha-2 antagonistic activity is obtained by administering an agent having histamine H1 receptor agonist activity. A combined dosage form comprising an agent having 5HT2/5HT3 and alpha-2 antagonistic activity and an agent having histamine H1 receptor agonist activity is presented. Some embodiments of the combined dosage form comprise an immediate release component comprising an agent having 5HT2/5HT3 and alpha-2 antagonistic activity and a delayed release component comprising an agent having histamine H1 receptor agonist activity. Some embodiments of the combined dosage form comprise a delayed release component comprising an agent having 5HT2/5HT3 and alpha-2 antagonistic activity and an immediate release component comprising an agent having histamine H1 receptor agonist activity. Methods of treatment and kits for administration are also provided.
• [EN] IMPROVING THE TOLERABILITY OF MIRTAZAPINE AND A SECOND ACTIVE BY USING THEM IN COMBINATION<br/>[FR] AMÉLIORATION DE LA TOLÉRANCE À LA MIRTAZAPINE ET À UN SECOND PRINCIPE ACTIF PAR UTILISATION COMBINÉE DE CES DERNIERS
  申请人：CYPRESS BIOSCIENCE INC

  公开号：WO2008157094A1

  公开（公告）日：2008-12-24

  [EN] A reduction in the side effects of treating with an agent having combined 5HT2/5HT3and alpha-2 antagonistic activity is obtained by administering an agent having selective norepinephrine reuptake inhibitory or histamine H1 agonist activity. A combined dosage form comprising an agent having 5HT2/5HT3and a1pha-2 antagonistic activity and an agent having selective norepinephrine reuptake inhibitory or histamine H1 agonist activity is presented. Some embodiments of the combined dosage form comprise an immediate release component comprising an agent having 5HT2/5HT3and alpha-2 antagonistic activity and a delayed release component comprising an agent having selective norepinephrine reuptake inhibitor or histamine HI agonist activity. Some embodiments of the combined dosage form comprise a delayed release component comprising an agent having 5HT2/5HT3 and alpha-2 antagonistic activity and an immediate release component comprising an agent having selective norepinephrine reuptake inhibitor or histamine H1 agonist activity. Methods of treatment and kits for administration are also provided
  [FR] La présente invention concerne la diminution des effets secondaires en cours de traitement avec un agent ayant une activité antagoniste 5HT2/5HT3 et alpha-2 combinée. Cette diminution des effets secondaires s'obtient en administrant un agent ayant une activité inhibitrice sélective de la recapture de la norépinéphrine ou bien une activité agoniste de l'histamine H1. Une forme de dosage combiné comprenant un agent ayant une activité antagoniste 5HT2/5HT3 et alpha-2 ainsi qu'un agent ayant une activité inhibitrice sélective de la recapture de la norépinéphrine ou bien une activité agoniste de l'histamine H1 est présentée. Certaines formes de réalisation de la forme de dosage combiné comprennent un composant à libération immédiate contenant un agent à activité antagoniste 5HT2/5HT3 et alpha-2, ainsi qu'un composant à libération retardée comprenant un agent ayant une activité inhibitrice sélective de la recapture de la norépinéphrine ou une activité agoniste de l'histamine H1. Certaines formes de réalisation de la forme de dosage combiné comprennent un composant à libération retardée contenant un agent à activité antagoniste 5HT2/5HT3 et alpha-2, ainsi qu'un composant à libération immédiate comprenant un agent ayant une activité inhibitrice sélective de la recapture de la norépinéphrine ou une activité agoniste de l'histamine H1. L'invention concerne également des procédés de traitement et des kits d'administration associés.